stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Total debt
Vericel Corporation's total debt at the end of fiscal 2022 was $47.6M, down 5.12% from $50.2M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $85.1M. Over the past ten years it has ranged from $10.1M (fiscal 2016) to $53.3M (fiscal 2020); the current reading is higher than 67% of that period. Vericel Corporation ranks 99th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $47.6M | (5.12%) |
| FY2021 | $50.2M | (5.85%) |
| FY2020 | $53.3M | 91.35% |
| FY2019 | $27.9M | 61.58% |
| FY2017 | $17.2M | 70.72% |
| FY2016 | $10.1M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $85.1M | 1.98% |
| Jun 2023 | $83.4M | 77.92% |
| Mar 2023 | $46.9M | (1.53%) |
| Dec 2022 | $47.6M | (1.06%) |
| 29 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. compare | $264.3M |
| ADMA ADMA Biologics Inc compare | $198.9M |
| VCEL Vericel Corporation | $85.1M |
| VERA Vera Therapeutics, Inc. compare | $75.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $39.0M |
| PVLA Palvella Therapeutics, Inc. compare | $12.3M |
| CLDX Celldex Therapeutics, Inc. compare | $1.2M |
| PHVS Pharvaris N.V. compare | $559.6K |
| IMNM Immunome, Inc. compare | $228.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement